Correlation of estimated glomerular filtration rate with incidence of in-stent restenosis in patients with drug-elu-ting stent

doi:10.16150/j.1671-2870.2020.03.017

Abstract

Abstract:

Objective: To evaluate correlation of estimated glomerular filtration rate with occurrence of in-stent restenosis (ISR) in patients treated with drug-eluting stent(DES) implantation during follow-up period. Methods: Patients undergone DES implantation in the RIPPER study between January 2010 and July 2016 were enrolled, and coronary angiography was performed again to detect ISR after 12-24 months (with the average time of 13 months). Binary Logistics regression were used to assess the risk factors for in-stent restenosis (ISR), and evaluate the correlation of eGFR with ISR in patients. Results: A total of 1 790 patients meeting the inclusion criteria, with the average eGFR of 89.97 mL/(min·1.73 m²) during follow-up, were divided into ISR group (n=200) and No-ISR group (n=1 590). The eGFR in ISR group was significantly lower than No-ISR group [(86.50±25.69) mL/(min·1.73 m²) vs. (90.64±26.59) mL/(min·1.73 m²), P=0.038]. Binary Logistics regression showed that the risk factors for ISR were number of implanted stent[OR=1.478, 95% CI 1.177-1.855, P=0.001] and increased baseline C-reactive protein level [OR=1.006, 95%CI 1.002-1.011, P=0.007], while relatively elevated eGFR during follow-up was protective factor（OR=0.990, 95%CI 0.982-0.999, P=0.022.Conclusions: In patients with nearly normal eGFR after DES implantation, relatively lower eGFR is correlated with the incidence of ISR.

Key words: Estimated glomerular filtration rate, Drug eluting stent, Restenosis, Logistics regression

CLC Number:

R541.4

LIU Shengjun, LIU Lili, ZHU Zhengbin, SUN Yi, ZHU Tianqi, FENG Shuo, CHEN Xin, QUAN Weiwei, ZHANG Ruiyan. Correlation of estimated glomerular filtration rate with incidence of in-stent restenosis in patients with drug-elu-ting stent[J]. Journal of Diagnostics Concepts & Practice, 2020, 19(03): 297-302.

Figures/Tables 4

References 22

[1]	Ene-Iordache B, Perico N, Bikbov B, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): A cross-sectional study[J]. Lancet Glob Health, 2016, 4(5):e307-e319. doi: 10.1016/S2214-109X(16)00071-1 URL
[2]	Mathew RO, Bangalore S, Lavelle MP, et al. Diagnosis and management of atherosclerotic cardiovascular di-sease in chronic kidney disease: A review[J]. Kidney int, 2017, 91(4):797-807. doi: S0085-2538(16)30625-1 pmid: 28040264
[3]	Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization[J]. Arch Intern Med, 2004, 164(6):659-663. doi: 10.1001/archinte.164.6.659 URL
[4]	Zhang L, Zhao MH, Zuo L, et al. China Kidney Disease Network (CK-NET) 2015 Annual Data Report[J]. Kidney Int Suppl, 2019, 9(1):e1-e81.
[5]	国家心血管病中心. 中国心血管病报告2018[M]. 北京: 中国大百科全书出版社, 2018.
[6]	Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: A cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. doi: 10.1016/S0140-6736(12)60033-6 URL
[7]	Zhang L, Wang H, Long J, et al. China Kidney Disease Network (CK-NET) 2014 Annual Data Report[J]. Am J kidney Dis, 2017, 69(6S2):A4.
[8]	Ishimoto Y, Tanaka T, Yoshida Y, et al. Physiological and pathophysiological role of reactive oxygen species and reactive nitrogen species in the kidney[J]. Clin Exp Pharmacol Physiol, 2018, 45(11)1097-1105. doi: 10.1111/1440-1681.13018 URL
[9]	Spoto B, Pisano A, Zoccali C, et al. Insulin resistance in chronic kidney disease: a systematic review[J]. Am J Physiol Renal Physiol, 2016, 311(6):F1087-F1108. doi: 10.1152/ajprenal.00340.2016 URL
[10]	Horowitz B, Miskulin D, Zager P, et al. Epidemiology of hypertension in CKD[J]. Adv Chronic Kidney Dis, 2015, 22(2):88-95. doi: 10.1053/j.ackd.2014.09.004 URL
[11]	王芳, 章安迪. 伴有多种危险因素的冠心病患者支架内再狭窄的影响因素[J]. 诊断学理论与实践, 2016, 15(3):280-282.
[12]	Welt FG, Rogers C. Inflammation and restenosis in the stent era[J]. Arterioscler Thromb Vasc Biol, 2002, 22(11):1769-1776. doi: 10.1161/01.ATV.0000037100.44766.5B URL
[13]	Gross ML, Meyer HP, Ziebart H, et al. Calcification of coronary intima and media: Immunohistochemistry, backscatter imaging, and X-ray analysis in renal and nonrenal patients[J]. Clin J Am Soc Nephrol, 2007, 2(1):121-134. doi: 10.2215/CJN.01760506 URL
[14]	Ishibashi M, Hiasa K, Zhao Q, et al. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling[J]. Circ Res, 2004, 94(9):1203-1210. pmid: 15059935
[15]	张瑞岩, 慢性肾病对冠心病发病和预后的影响[J]. 内科理论与实践, 2006, 3(2):94-98.
[16]	Kaul U, Bhagwat A, Pinto B, et al. Paclitaxel-eluting stents versus everolimus-eluting coronary stents in a diabetic population: Two-year follow-up of the TUXEDO-India trial[J]. EuroIntervention, 2017, 13(10):1194-1201. doi: 10.4244/EIJ-D-17-00333 URL
[17]	Sedlis PS, Jurkovitz CT, Hartigan PM, et al. Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease[J]. Am J Cardiol, 2009, 104(12):1647-1653. doi: 10.1016/j.amjcard.2009.07.043 URL
[18]	Khalique O, Aronow WS, Ahn C, et al. Relation of moderate or severe reduction in glomerular filtration rate to number of coronary arteries narrowed >50% in patients undergoing coronary angiography for suspected coronary artery disease[J]. Am J Cardiol, 2007, 100(3):415-416. pmid: 17659920
[19]	Rostand SG, Gretes JC, Kirk KA, et al. Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis[J]. Kidney Int, 1979, 16(5):600-611. doi: 10.1038/ki.1979.170 pmid: 548604
[20]	Schwarz U, Buzello M, Ritzet E, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure[J]. Nephrol Dial Transplant, 2000, 15(2):218-223. doi: 10.1093/ndt/15.2.218 URL
[21]	曹立秀, 张欢, 肖华, 等. 中-重度肾功能不全患者冠状动脉病变的CT诊断研究[J]. 诊断学理论与实践, 2011, 10(6):523-526.
[22]	Kato K, Yonetsu T, Jia H, et al. Nonculprit coronary plaque characteristics of chronic kidney disease[J]. Circ Cardiovasc imaging, 2013, 6(3):448-456. doi: 10.1161/CIRCIMAGING.112.000165 URL

项目	无ISR组(n=1 590)	ISR组(n=200)	P值
临床特征
年龄（岁）	63.45±10.79	63.09±10.15	0.658
男性 [n(%）]	1 169(73.5%)	147(73.5%)	0.995
体质量指数（kg/m²）	25.46±3.22	25.49±3.4	0.919
基线期收缩压（mmHg）	131.48±17.46	130.82±16.61	0.613
基线期舒张压（mmHg）	78.15±10.62	77.5±10.81	0.415
随访期收缩压（mmHg）	130.11±15.24	131.27±16.82	0.316
随访期舒张压（mmHg）	77.29±9.60	77.51±10.42	0.758
基线期射血分数（%）	61.59±8.36	62.17±7.72	0.366
随访期射血分数（%）	61.94±8.02	61.27±8.75	0.287
冠脉造影信息
2次造影间隔时间（d）	446.75±102.06	456.87±100.70	0.186
植入支架数^*（个）	1 (1~2)	1 (1~2)	0.006
平均支架长度（mm）	26.0 (19.8~33.4)	28.0 (20.9~34.9)	0.171
合并症
高血压[n（%）]	1 017(64.0%)	135(64.0%)	0.325
糖尿病[n（%）]	908(57.1%)	112(57.1%)	0.766
高脂血症[n（%）]	241(15.2%)	35(15.2%)	0.387
慢性肾病病史[n（%）]	31(1.9%)	3(1.9%)	0.661
急性冠脉综合征病史[n（%）]	267(16.8%)	41(16.8%)	0.190
外周血管病史[n（%）]	128(8.1%)	15(8.1%)	0.787
卒中病史[n（%）]	87(5.5%)	16(5.5%)	0.148
吸烟史[n（%）]	674(42.4%)	89(42.4%)	0.570
药物治疗
P2Y12受体拮抗剂使用 [n（%）]	1 526(96.0%)	190(96.0%)	0.514
降脂药使用[n（%）]	1 538(96.7%)	193(96.7%)	0.864
ACEI和（或）ARB使用[n（%）]	911(57.3%)	114(57.3%)	0.937
β受体阻滞剂使用[n（%）]	1 162(73.1%)	144(73.1%)	0.745

项目	基线期			随访期
项目	无ISR组	ISR组	P值	无ISR组	ISR组	P值
肾功能相关指标
尿酸（μmol/L）	335.97±96.20	334.12±97.49	P>0.05	334.12±97.49	337.95±91.21	P>0.05
eGFR[mL/(min·1.73 m²)]	91.53±27.53	88.10±26.27	P<0.05	88.10±26.27	86.50±25.69	P<0.05
其他实验室指标
C反应蛋白（mg/L）	1.6(0.7~5.1)	2.6(0.8~8.5)	P>0.05	2.6(0.8~8.5)	0.9(0.5~2.5)	P>0.05
空腹血糖（mmol/L）	6.19±2.36	6.53±3.16	P>0.05	6.53±3.16	6.19±2.26	P>0.05
总胆固醇（mmol/L）	4.25±1.20	4.19±1.14	P>0.05	4.19±1.14	3.64±0.87	P>0.05
甘油三酯（mmol/L）	1.84±1.30	1.72±1.14	P>0.05	1.72±1.14	1.59±1.24	P>0.05
高密度脂蛋白胆固醇（mmol/L）	1.05±0.29	1.07±0.28	P>0.05	1.07±0.28	1.08±0.31	P>0.05
低密度脂蛋白胆固醇（mmol/L）	2.50±0.93	2.44±0.86	P>0.05	2.44±0.86	2.01±0.68	P>0.05

项目	单因素分析	多因素分析
项目	P值	β值	P值	OR(95% CI)
性别(男性) [n(%）]	0.995	-0.163	0.379	0.850(0.592~1.221)
年龄（岁）	0.658	-0.024	<0.001	0.976(0.968~0.984)
糖尿病 [n（%）]	0.766	-0.162	0.324	0.851(0.617~1.173)
吸烟史 [n（%）]	0.570	0.070	0.673	1.073(0.773~1.489)
植入支架数（个）	0.006	0.391	0.001	1.478(1.177~1.855)
基线空腹血糖（mmol/L）	0.080	0.042	0.174	1.043(0.982~1.108)
基线期C反应蛋白（mg/L）	0.064	0.006	0.007	1.006(1.002~1.011)
基线期eGFR[mL/(min·1.73 m²)]	0.097	-0.004	0.363	0.996(0.988~1.004)
随访期eGFR（mL/(min·1.73 m²)）	0.038	-0.010	0.022	0.990(0.982~0.999)